Skip to Main Content

Paper Details

Anti-GD2 synergizes with CD47 blockade to mediate tumor eradication.
Nat Med
94
2022
Anti-, CD47, GD2, GD2 malignancy, GD2-specific factors, Macrophages, anti-, anti-CD47, anti-GD2, calreticulin, children, disialoganglioside GD2, macrophage, mouse, neuroblastoma, osteosarcoma, patients, small-cell lung cancer, solid tumors, tumor, tumor cells, tumors
Author NameAffiliation
Garry L ColesStanford University School of Medicine
Garry L ColesStanford Cancer Institute, Stanford University School of Medicine
Alberto Delaidelli
Jaume Pons
Jose G Vilches-MoureStanford University School of Medicine
Michelle MonjeStanford University School of Medicine
Michelle MonjeStanford University School of Medicine
Michelle MonjeLudwig Center for Cancer Stem Cell Research and Medicine, Stanford University School of Medicine
Michelle MonjeStanford University
Michelle MonjeStanford Cancer Institute, Stanford University School of Medicine
Michelle MonjeInstitute for Stem Cell Biology and Regenerative Medicine
Poul H Sorensen
Poul H Sorensen
Julien SageStanford University School of Medicine
Julien SageStanford Cancer Institute, Stanford University School of Medicine
Ravindra MajetiInstitute for Stem Cell Biology and Regenerative Medicine
Ravindra MajetiStanford Cancer Institute, Stanford University School of Medicine
Ravindra MajetiStanford University School of Medicine
Ravindra MajetiLudwig Center for Cancer Stem Cell Research and Medicine, Stanford University School of Medicine
Carolyn R BertozziChEM-H Institute, Stanford University
Carolyn R BertozziStanford University
William A WeissBrain Tumor Research Center, University of California san francisco
William A WeissBrain Tumor Research Center, University of California san francisco
  • 1 - 23

Datasets

Release 1.2